ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Head-to-Head comparison of [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Pooled it
- Trial
- Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Trial
- Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study.Scientific reports · 2018Trial
- Prediction of neoadjuvant chemotherapy response using diffuse optical spectroscopy in breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Trial
- Macrocycle Chelator Conjugation on the C3 Hydroxyl Group of 17β-Estradiol reduces Estrogen Receptor Binding.Molecular imaging and biology · 2026Article
- Clinical impact ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.Breast (Edinburgh, Scotland) · 2026Review
- Article
- Novel 4D radiomics applied to dynamic FES PET images to improve prediction of breast cancer response to ER-targeted therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Hybrid [AJNR. American journal of neuroradiology · 2025Article
- Automated Tools to Analyze FES PET: Translational Potential to Guide Therapy in Estrogen Receptor Positive Breast Cancer.Radiology. Imaging cancer · 2025Article
- [18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast Cancer.Molecular imaging and biology · 2025Article
- [EJNMMI research · 2025Article
- Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2- breast cancer.Cell reports. Medicine · 2025Article
- Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer.Breast cancer research : BCR · 2025Article
- Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives.Clinical & experimental metastasis · 2024Review
- Exploring Radioiodinated Anastrozole and Epirubicin as AKT1-Targeted Radiopharmaceuticals in Breast Cancer: In Silico Analysis and Potential Therapeutic Effect with Functional Nuclear Imagining Implications.Molecules (Basel, Switzerland) · 2024Article
- Radiotracer Innovations in Breast Cancer Imaging: A Review of Recent Progress.Diagnostics (Basel, Switzerland) · 2024Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
purposeEXPERIMENTAL
designNinety patients with breast cancer from an estrogen receptor-positive (ER
resultsRecursive partitioning with 5-fold internal cross-validation used both FES PET and FDG PET measures to classify patients into three distinct response groups. FDG PET identified 24 patients (29%) with low FDG uptake, suggesting indolent tumors. These patients had a median PFS of 26.1 months (95% confidence interval, 11.2-49.7). Of patients with more FDG-avid tumors, 50 (59%) had high average FES uptake, and 10 (12%) had low average FES uptake. These groups had median PFS of 7.9 (5.6-11.8) and 3.3 months (1.4-not evaluable), respectively. Patient and tumor features did not replace or improve the PET measures' prediction of PFS. Prespecified endocrine resistance classifiers identified in smaller cohorts did not individually predict PFS.
conclusionsA wide range of therapy regimens are available for treatment of ER
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.